Is GRAIL Inc. (GRAL) a Buy, Sell, or Hold?
NASDAQ : GRAL
GRAIL Inc.
$64.42 USD
-$2.35 (-3.52%)
- Volume
- 789.35K
- Average Volume
- 672.58K
- Market Capitalization
- $2.76B
- P/E Ratio
- -6.21
- Dividend Yield
- 0.00%
- Price Target
- $62.50
- Year High
- $118.84
- Year Low
- $29.95
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $11.74
Company Overview
NASDAQ
Joshua J. Ofman
Biotechnology
Healthcare
GRAL
910
US
USD
Liquidity Metrics
0.02
11.74
11.51
0.93
0.00
Sales & Valuation
$147.17M
17.71
1.05
-9.49
-7.17
Profitability
-$11.11
-$408.35M
-253.22%
-330.27%
-16.42%
-14.10%
P/E Metrics
-6.21
-0.05
-0.05
Analyst Price Target & Rating
$62.50
$80.00
$56.00
2/5
7 Analysts
3.07%
Financial Health Scores
0.44
4/9
$802.64M
$2.8B
$302.79M
-$493.61M
Key Metrics (TTM)
$2.85B
18.24
-8.43
11.74
-16.42%
-15.24%
-14.57%
-10.17%
73 days
Company Executives
| Name | Title |
|---|---|
| Aaron Freidin | CFO & Head of Corporate Development |
| Eric T. Fung | Senior Vice President of Clinical Development |
| Joshua J. Ofman | Chief Executive Officer & Director |
| Satnam Alag | Chief Technology Officer |
| Andrew John Partridge | Chief Growth Officer |
| Paul Ciccolella | Senior Vice President of Global Development & Operations |
| Alison Highlander | Chief People Officer |
| Trish Rowland | Senior Vice President of Corporate Communications |
| Sir Harpal S. Kumar | Chief Scientific Officer and President of Global Clinical & Medical Affairs |
| Robert Ragusa | Advisor |
| Alexis Tosti | Vice President of Strategy & Corporate Development |
| Abram Barth | Chief Legal Officer & Corporate Secretary |
| Erin Polak | Senior Vice President of Government Affairs, Policy, and Alliance Development |
Poll Results
No votes yet today — be the first to share your view!
About GRAIL Inc. (NASDAQ:GRAL) Stock
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 20 ... 15 and is headquartered in Menlo Park, California.
GRAL Deadline: GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
2026-07-28 18:51:00
NEW YORK, July 28, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminders purchasers of common stock of GRAIL, Inc. (NASDAQ: GRAL) between May 13, 2025 and February 19, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.
Grail, Inc. (GRAL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
2026-07-28 18:49:00
LOS ANGELES, July 28, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Grail, Inc. ("Grail" or the "Company") (NASDAQ: GRAL). IF YOU SUFFERED A LOSS ON YOUR GRAIL, INC.
2026-07-28 17:23:00
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against GRAIL, Inc. (“Grail” or the “Company”) (NASDAQ: GRAL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
2026-07-28 16:00:00
SAN FRANCISCO, July 28, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in GRAIL, Inc. (NASDAQ: GRAL) that a securities fraud class action lawsuit has been filed, and the firm is actively urging investors with substantial losses to submit your losses now . The upcoming lead plaintiff deadline is August 4, 2026.
2026-07-28 12:21:00
PHILADELPHIA, July 28, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) ("GRAIL" or the "Company") on behalf of investors who purchased or acquired GRAIL common stock during the period from May 13, 2025 through February 19, 2026 (the "Class Period"). Investor Deadline: Investors who purchased or acquired GRAIL common stock during the Class Period may, no later than August 4, 2026 , seek to be appointed as a lead plaintiff representative of the class.
Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors
2026-07-28 11:22:00
LOS ANGELES, July 28, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Grail, Inc., (“Grail” or the "Company") (NASDAQ: GRAL) investors of a class action on behalf of investors that bought securities between May 13, 2025 and February 19, 2026, inclusive (the “Class Period”). Grail investors have until August 4, 2026 to file a lead plaintiff motion.
2026-07-28 10:23:00
Key Dates and Disclosure Events Shareholders Need to Know: From Positive Top-Line Results to a 50.55% Stock Collapse, the Chronology of Grail's NHS-Galleri Trial Reveals an Escalating Pattern of Alleged Investor Harm Key Dates and Disclosure Events Shareholders Need to Know: From Positive Top-Line Results to a 50.55% Stock Collapse, the Chronology of Grail's NHS-Galleri Trial Reveals an Escalating Pattern of Alleged Investor Harm
2026-07-28 10:10:00
SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in GRAIL, Inc. (NASDAQ: GRAL) that a securities fraud class action lawsuit has been filed, and the firm is actively urging investors with substantial losses to submit your losses now . The upcoming lead plaintiff deadline is August 4, 2026.
Frequently Asked Questions
-
What is the current GRAIL Inc. (GRAL) stock price?
-
GRAIL Inc.(NASDAQ:GRAL) stock price is $64.42 in the last trading session. During the trading session, GRAL stock reached the peak price of $118.84 while $29.95 was the lowest point it dropped to. The percentage change in GRAL stock occurred in the recent session was --3.52% while the dollar amount for the price change in GRAL stock was -$2.35.
-
GRAL's industry and sector of operation?
-
The NASDAQ listed GRAL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GRAL?
-
Aaron Freidin | CFO & Head of Corporate Development
Eric T. Fung | Senior Vice President of Clinical Development
Joshua J. Ofman | Chief Executive Officer & Director
Satnam Alag | Chief Technology Officer
Andrew John Partridge | Chief Growth Officer -
How many employees does GRAL have?
-
Number of GRAL employees currently stands at 910. GRAL operates from 1525 O’Brien Drive, Menlo Park, CA 94025, US.
-
Link for GRAL official website?
-
Official Website of GRAL is: http://www.grail.com
-
How do I contact GRAL?
-
GRAL could be contacted at phone #833-694-2553 and can also be accessed through its website. GRAL operates from 1525 O’Brien Drive, Menlo Park, CA 94025, US.
-
How many shares of GRAL are traded daily?
-
The average number of GRAL shares traded daily for last 3 months was 672.58K.
-
What is the market cap of GRAL currently?
-
The market value of GRAL currently stands at $2.76B with its latest stock price at $64.42